Invitrocue (ASX:IVQ) has established a joint innovation laboratory with the Genome Institute of Singapore to develop cancer organoids to better guide clinical decision in cancer management.
Invitrocue is a provider of bio-analytic solutions including in vitro cell-based testing technologies and image analytics software for use in digital pathology.
The Genome Institute of Singapore (GIS) is a government supported initiative which seeks to use genomic sciences to achieve significant improvements in human health.
The GIS- Invitrocue joint laboratory aims to develop tumour models to enhance decision-making for clinicians, and enable them to personalise treatment to help patients manage the disease.
The laboratory will focus on four oncology indications which include head and neck cancer, colorectal cancer, liver cancer and triple negative breast cancer.
As one of the world’s leading centres for genomic discovery, GIS pursues the integration of technology, genetics and biology towards the goal of individualised medicine.
The joint laboratory will leverage GIS’ expertise in genomics, oncology and organoid biology, and Invitrocue’s capabilities in developing cell-based products and services for commercialisation.
Over time the laboratory will employ up to 20 personnel in various scientific and technical roles.
Invitrocue has also partnered with groups in Australia, such as the Garvan Institute of Medical Research to scale its efforts.